Results 81 to 90 of about 43,675 (258)

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange   +16 more
wiley   +1 more source

Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia

open access: yesMolecular & Cellular Oncology, 2017
The polycomb protein enhancer of zeste homolog 2 (EZH2) may have a dual role in cancer pathogenesis acting as an oncogene or as a tumor suppressor depending on the cancer type.
Stefanie Göllner, Carsten Müller-Tidow
doaj   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing   +6 more
wiley   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

COMPARISON OF EZH2, BCL-2, BER-EP4, AND CK20 EXPRESSION WITH THE KI67 PROLIFERATIVE INDEX AND OTHER ADVERSE CLINICAL INDICATORS, AND COMPARISON OF EXPRESSION WITH THE MORPHOLOGICAL TYPE OF BASAL CELL CARCINOMA [PDF]

open access: yesJournal of IMAB
Introduction: Basal cell carcinoma (BCC) is the most common cutaneous malignant tumor, characterized by locally invasive growth and low metastatic potential. The role of immunohistochemical markers such as EZH2, Bcl-2, Ber-EP4, and Ki67 in the assessment
Boyana Anatolieva   +2 more
doaj   +1 more source

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

Reversing brain aging: Targeting energy metabolism in endogenous neural stem cells

open access: yesInterdisciplinary Medicine, EarlyView.
Mechanism of endogenous neural stem cells (eNSCs) energy metabolism disorder leading to brain aging and targeted eNSCs intervention strategies (By biorender). The disorder of energy metabolism of eNSCs can lead to their resting and aging, and eventually lead to brain aging.
Chong Chen   +6 more
wiley   +1 more source

NRF1 predominantly causes EZH2 overexpression in cancer cells

open access: yesCell Death and Disease
EZH2 is an oncogene and therapeutic target. Only a small proportion of cancer patients benefit from treatment with EZH2 inhibitors (EZH2is). The mechanisms underlying EZH2 overexpression and EZH2i resistance are not clear.
Juanli Qiao   +3 more
doaj   +1 more source

RBMX Transcriptionally Repressed by EZH2‐Associated H3K27me3 Modification Attenuates Pyroptosis in Renal Ischemia/Reperfusion Injury via Regulating SIRT3/NLRP3 Inflammasome Activation

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ischemic reperfusion injury (IRI) to kidney is a significant clinical factor in acute kidney injury (AKI). This study aimed to investigate the new role of RNA‐binding motif protein X‐linked (RBMX), a modulator of m6A methylation, in renal IRI and to examine the associated regulatory mechanisms. An in vitro renal IRI model was established using
Yi‐Han Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy